Eco Animal Health Group PLC Share Awards to Executive Directors
October 28 2024 - 8:57AM
RNS Regulatory News
RNS Number : 9038J
Eco Animal Health Group PLC
28 October 2024
28 October
2024
ECO Animal Health Group
plc
("ECO" or
the "Company")
Share Awards to Executive
Directors
ECO
Animal Health Group plc (AIM: EAH), a rapidly growing global
animal health company with a portfolio of marketed veterinary
products and a maturing proprietary R&D pipeline, announced
that on 27 October 2024, nominal cost conditional share options
were granted under the Company's Long Term Incentive Plan (the
"LTIP") over 329,811 ordinary shares in the Company (representing
approximately 0.49 percent of the Company's issued share capital)
to Executive Directors listed below.
|
Name
|
Position
|
Number of Share
Awards
|
|
David Hallas
|
Chief Executive Officer
|
189,531
|
|
Chris Wilks
|
Chief Financial Officer
|
140,280
|
These awards under the LTIP are subject to
performance conditions being met which have been set by the
Company's Remuneration Committee and relate to Total Shareholder
Return ("TSR") and Research and Development ("R&D") targets.
Subject to the performance conditions being met, awards will vest
after the end of a three-year vesting period. Further details on
the LTIP can be found in the Company's 2024 Annual
Report.
-Ends-
For further
information please contact:
|
ECO Animal
Health Group plc
David Hallas (CEO)
Christopher Wilks (CFO)
|
020 8447 8899
|
|
Singer Capital
Markets (Nominated Adviser & Joint Broker)
Phil Davies
Sam Butcher
|
020 7496 3000
|
|
Investec
(Joint Broker)
Gary Clarence
Lydia Zychowska
|
020 7597 5970
|
|
Equity
Development
Hannah Crowe
Matt Evans
|
020 7065 2692
|
|
ICR Consilium
(Financial PR)
Mary-Jane Elliott
Jessica Hodgson
|
020 3709 5700
ecoanimalhealth@consilium-comms.com
|
|
|
About ECO
Animal Health
ECO Animal Health is a world leader in animal
health, developing and marketing branded veterinary pharmaceuticals
globally, with expertise in antibiotics and vaccines for pigs and
poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices
including R&D and manufacturing, we have marketing
authorisations in over 70 countries and employ over 200 people
worldwide.
Our lead product, Aivlosin® is a proprietary,
patented medication which is effective against both respiratory and
intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
PDMR Notification - ECO LTIP Nominal Cost Conditional Share
Awards
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a.
|
Name
|
David Hallas
|
|
2.
|
Reason for the notification
|
|
a.
|
Position/status
|
Chief Executive Officer
|
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Eco Animal Health Group Plc
|
|
b.
|
LEI
|
2138009XN9DJ3YP70B55
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the
Financial instrument, type of
instrument
Identification code
|
Options over ordinary shares of 5p
each.
GB0032036807
|
|
b.
|
Nature of the transaction
|
Award of nominal cost conditional
share awards under the Company's LTIP.
|
|
c.
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
5p
|
189,531
|
|
|
d.
|
Aggregated information
Aggregated volume
Price
|
n/a
|
|
e.
|
Date of the transaction
|
27 October 2024
|
|
f.
|
Place of the transaction
|
Off Market
|
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a.
|
Name
|
Chris Wilks
|
|
2.
|
Reason for the notification
|
|
a.
|
Position/status
|
Chief Financial Officer
|
|
b.
|
Initial notification
/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a.
|
Name
|
Eco Animal Health Group Plc
|
|
b.
|
LEI
|
2138009XN9DJ3YP70B55
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a.
|
Description of the
Financial instrument, type of
instrument
Identification code
|
Options over ordinary shares of 5p
each.
GB0032036807
|
|
b.
|
Nature of the transaction
|
Award of nominal cost conditional
share awards under the Company's LTIP.
|
|
c.
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
5p
|
140,280
|
|
|
d.
|
Aggregated information
Aggregated volume
Price
|
n/a
|
|
e.
|
Date of the transaction
|
27 October 2024
|
|
f.
|
Place of the transaction
|
Off Market
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHLVLFLZBLEFBE
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Oct 2024 to Nov 2024
Eco Animal Health (LSE:EAH)
Historical Stock Chart
From Nov 2023 to Nov 2024
